Serum visfatin levels in patients with atopic dermatitis and cutaneous T-cell lymphoma

Hiraku Suga, Makoto Sugaya, Tomomitsu Miyagaki, Makiko Kawaguchi, Sohshi Morimura, Hiromichi Kai, Shinji Kagami, Hanako Ohmatsu, Hideki Fujita, Yoshihide Asano, Yayoi Tada, Takafumi Kadono, Shinichi Sato

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Visfatin, a novel adipocytokine, is related with chronic inflammatory diseases, especially those characterized by T helper (Th)1-type immune responses. In this study, we examined serum visfatin levels in patients with atopic dermatitis (AD) or cutaneous T-cell lymphoma (CTCL), both of which are Th2-dominant diseases. Serum visfatin levels in patients with AD or advanced stage CTCL were significantly elevated compared to healthy controls. In CTCL patients, serum visfatin levels significantly decreased after treatment. Serum visfatin levels correlated with eosinophil counts inADpatients, whereas they correlated with the visual analogue scale itch scores and serum C-C motif ligand (CCL) 11 and CCL26 levels in CTCL patients. Visfatin expression by adipose tissue in lesional skin of AD and advanced stage CTCL was enhanced compared to that of healthy controls. These results suggest that visfatin may also be important in the development of Th2-dominant diseases as well as in Th1-type diseases.

Original languageEnglish
Pages (from-to)629-635
Number of pages7
JournalEuropean Journal of Dermatology
Issue number5
Publication statusPublished - 2013 Sept
Externally publishedYes


  • Adipose tissue
  • Atopic dermatitis
  • Cutaneous T-cell lymphoma
  • Mycosis fungoides
  • Visfatin

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Serum visfatin levels in patients with atopic dermatitis and cutaneous T-cell lymphoma'. Together they form a unique fingerprint.

Cite this